168 results about "Digoxin" patented technology

The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.

A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

The present invention relates to gene chip detection method and is one using no radioactive label and no fluorescent label. The detection method includes the following steps: extracting the tested target gene in sample, labeling the gene with digoxin or biotin to obtain labeled DNA or RNA for hybridization with the gene chip; making nano gold labeled digoxin antibody to combined with digoxin or nano gold labeled avidin to combine with biotin; dyeing the hybridized gene chip with silver dyeing reagent; direct microscope oservation, CCD record of signal or scanning detection with common opticalscanning instrument to obtain corresponding crossing result; and further analysis by using relative software.

The invention relates to a method for differentiating indica japonica of weedy rice through two repeated DNA (Deoxyribonucleic Acid) sequences. In the method, plasmid DNAs of cloning pTA71 containing wheat 45SrDNA gene sequences and cloning pOs48 containing repeated serial sequences of subtelocentric rice AA group chromosome are extracted, and 45SrDNA and Os48 probes are formed by using pOs48 labeled by using digoxin-dUTP (deoxyuridine triphosphate) and pTA71 labeled by using biotin-dUTP through a nick translation method to differentiate the indica japonica of the weedy rice. The method comprises the following steps of: flaking and denaturing a metaphase chromosome of the differentiated weedy rice before karyokinesis; carrying out two-color fluorescence in-situ hybridization between the metaphase chromosome and a denatured hybridization solution containing the probes; detecting a signal of the metaphase chromosome in the dark; and classifying the indica japonica of the weedy rice of different sources according to the locus number and distribution characteristics of the 45SrDNA and the Os48 on the metaphase chromosome of the weedy rice before the karyokinesis.

The invention provides an extraction-free direct-amplification rapid detection method for SNP typing of a human MTHFR gene via test strips. The method comprises the following steps: step 1, mixing samples with a sample treatment fluid and carrying out standing for 5 min, wherein obtained mixtures are used as templates; step 2, separately designing a wild specific primer, a mutant specific primer and a shared primer for identification and amplification of the C677T SNP site of a to-be-detected MTHFR gene, wherein the 5'-terminals of the wild specific primer and the mutant specific primer are both labeled with digoxin and the 5'-terminal of the shared primer is both labeled with biotin; step 3, carrying out parallel two-tube PCR reactions on each sample so as to obtain amplification products; and step 4, subjecting the amplification products obtained in the step 3 to typing detection via the test strips by using chromatographic techniques and action between digoxin and a digoxin monoclonal antibody and between biotin and streptavidin, and then judging and determining genotypes.

The invention provides a method and a reagent kit for simultaneously detecting the resistance sites of the three nucleotide analogues of a hepatitis B virus (HBV). Based on the genotype sequence of the HBV, four nested amplification primers and twenty-seven wild resistance-detection oligonucleotides probes aiming at ten resistance sites are designed in an HBV polymerase area, digoxin-labeled oligonucleotides universal primers are used for conducting nested PRC reaction to amplify a target DNA segment, a target DNA amplification product to be labeled is used for hybridizing with specific oligonucleotide probes on matrix, and the existence of the resistance of the HBV to the three nucleotide analogues is judged through enzymatic color development reaction link-coupled by hybridization conjugates. The method improves the accuracy, the reliability and the sensitivity and can simultaneously detect the ten resistance sites of the three nucleotide analogues, thereby realizing the high-throughput, multi-site, economic and rapid detection and fitting to clinical needs in a better way. The method is of great significance to the realization of early detection and the proper guide of clinical personalized medication.

The invention discloses a method for screening paralytic shellfish poisoning generation strains by using a DNA probe-bacterial colony in-situ hybridization technique. The method comprises steps of pretreatment, hybridization and screening. By using specific forward primers and reverse primers, a single chain DNA probe marked by digoxin is synthesized through polymerase chain reaction amplification, DNA of a strain to be tested is hybridized with the DNA probe, and poisoning generation strains are screened according to developing testing hybridization matching results. The method has the beneficial effects that 90 samples can be screened within 8-10 hours by using the method disclosed by the invention, the method is rapid and efficient, good in specificity and high in accuracy, the method is simple in operation step, small in workload and relatively short in cycle, reagents and materials used in the method are all common reagents for biochemical tests, and thus the method is harmless tohuman bodies, environmental-friendly, low in analysis cost, relatively good in market prospect and high in economic value.

The invention provides an miRNA in-situ hybridization probe, its detection kit and its application. A fluorine atom is modified by a 2-carbon atom of the base five-carbon ring of the hybridization probe. The preferable sequence of the probe is represented by SEQ ID NO:1, wherein fluorine atoms are modified by 2-carbon atoms of third, sixth, fifteenth and twentieth base five-carbon rings. The other preferable sequence of the probe is represented by SEQ ID NO:2, wherein the fluorine atoms are modified by 2-carbon atoms of third, eighth, thirteenth and twenty-first base five-carbon rings. Digoxin is modified by 5' and 3' terminals of the probe. The invention also provides an in-situ hybridization detection kit of the hybridization probe. The probe of the invention can be applied to the preparation of miRNA in-situ hybridization detection kits for lung cancer cell lines or lung cancer tissues, and the preparation of miRNA in-situ hybridization detection kits for esophageal cancer cell lines or esophageal cancer tissues. The kit of the invention has the advantages of low price and good specificity.

The invention relates to an oligonucleotide microarray technique for detecting pathogen contamination in seawater, belonging to the field of seawater contamination monitoring. The technique comprises the main technical schemes that a 16S-23S rRNA gene transcription interval sequence is used as a detection target and is amplified by a one-step polymerase chain reaction, a digoxin mark is obtained simultaneously, and then oligonucleotide hybridization is carried out; and the obtained monitoring result is interpreted in a manner that an enzyme-labeled antibody catalyzes the substrate colour development. Compared with the traditional product for detecting seawater contamination, the invention utilizes microarray detection to obtain the distribution situation of large numbers of pathogens and contamination index bacteria, and has the advantage of high flux; the invention can directly utilize seawater as a sample and truly obtain the contamination situation information of target bacteria under a condition of keeping the natural proportion of the flora number in the seawater; however, most existing detection techniques need the step of enrichment culture, destroy the original proportion of a flora composition, have lower reliability of the result and have longer detection procedure; and the oligonucleotide microarray detection operation has short procedure and is comparatively sensitive and fast.

The invention provides a kit for determining the content of digoxin by using magnetic particulate chemiluminescent immunoassay, and a detection method thereof. The invention discloses a preparation method for digoxin antigen derivatives. The kit can realize indirect connection between a digoxin antigen and biotin or enzyme. Two detection systems are established in the kit, wherein one detection system is composed of a biotinylated digoxin antigen derivative, an enzyme-labelled antibody reagent and a calibrator, while the other detection system is composed of an enzyme-labelled digoxin antigenderivative, a biotinylated murine digoxi monoclonal antibody and the calibrator; so the kit is applicable to both solid-phase-coupled and luminescently-labeled digoxin derivatives and adapts to coupling of digoxin antigens with biotin, enzyme labels, or even proteins; and thus, different enterprises can flexibly use the kit during testing and only need to prepare the intermediates, i.e., the digoxin antigen derivatives, to realize testing. The correlations between given values and values measured by using different detection systems established by using the derivatives are 0.96 or more, and the correlation of the two detection systems is 0.9585. The kit of invention has the advantages that the whole reaction system is short in reaction time; radioactive pollution is avoided; the action period of reagents is realized; high sensitivity is obtained; testing results are accurate; and the flow of experimental operation is simplified.

The invention belongs to the field of biotechnologies, and particularly relates to a multi-PCR-ELISA detection kit for human seasonal influenza viruses and an application method thereof. The detection kit disclosed by the invention is composed of a RT-PCR reaction system, an ELISA detection system, four target-gene (an influenza-A-virus M gene, a H1 subtype virus HA gene, a H3 subtype virus HA gene, and a B type virus NS gene) positive plasmids (Pa-m, Ph1-ha, Ph3-ha and Pb-ns), a negative quality control specimen and four target-gene specific primer probes. Specific amplification is performed by using specific primers labeled by using four sets of biotins through RT-PCR, an amplified product after being denatured is hybridized with a specific probe labeled by using digoxin, a hybridized product is enveloped with a streptavidin-enveloped 96-hole micro-plate, and an anti-digoxin antibody labeled by using horse radish peroxidase is added for carrying out detection through an ELISA method, so that a rapid, sensitive and specific typing detection kit for seasonal influenza viruses such as H1 and H3 subtypes and hepatitis B viruses is established. The invention relates to the application of four sets of specific primer probes in the clinical differential diagnosis of influenza virus infection and the typing authentication of influenza virus isolates.

In the method, digoxin or biotin mark is added in the PCR augmentatino course of the sample to be tested and then the PCR product is hybridized with the chip, by adding colour developing liquid to obtain the correspounding signal after hybridizing and combining the antibody with digoxin or biotin mark. The correspounding results will be collected and detected with normal optical scanners scanning.

The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex.

The invention discloses a bacteria detecting technology which comprises designing special probes with biological information, including designing 34 pieces oligonucleotide as filtered probes and the corresponding PCR and hybridizing reacting conditions; enlarging via PCR and marking bacteria 16s-23srRNA gene interval array with Digoxin, and hybridizing the PCR products and a group of special oligonucleotide probes; after enzyme-linked immunoassay color-rendering, identifying whether has aquatic infectious pathogeny bacteria from the sample.

The invention belongs to the technical field of drug detection, and particularly relates to a method and a kit for detecting 19 drugs and metabolites thereof in blood through liquid chromatography-tandem mass spectrometry. The substances to be detected comprise sulpiride, pentafluridol, mianserin, buspirone, tandospirone, hydroxyazine, diazepam, venlafaxine, moclobemide, imipramine, paroxetine, reboxetine, amitriptyline, sertraline, digoxin, clonazepam, clopidogrel, toluenesulfobutyl urea, glimepiride, 1-pyrimidinepiperazine, desmethylvenlafaxine, 6-hydroxy buspirone and normipramine, and the substances to be detected are selected from the group consisting of sulpiride, pentafluridol, mianserin, venlafaxine, metandospirone, metandospirone, hydroxazine, diazepam, venlafaxine, moclobemide, the pharmaceutical composition is prepared from noramitriptyline, nordiazepam and clopidogrel metabolite; the detection method comprises the following steps: calibrating a standard solution, treating a to-be-detected sample, and detecting the to-be-detected sample by adopting high performance liquid chromatography-mass spectrometry. The embodiment of the invention can quickly and accurately measure the content, and the sample treatment method is simple and easy to implement, high in sensitivity and accurate in quantification.

The invention discloses a method for identifying all chromosomes of poplar by using oligonucleotide probes. The method comprises the following steps: obtaining a specific oligonucleotide sequence of each chromosome through bioinformatics analysis according to genome information of poplar tomentosa; synthesizing an oligonucleotide library corresponding to chromosome 1-19 of poplar; marking the oligonucleotide probes by using biotin or digoxin; identifying the chromosomes of the poplar by using a fluorescence in-situ hybridization technology; and repeatedly carrying out fluorescence in-situ hybridization for 7 times on the same metaphase splitting phase by using the oligonucleotide probes of up to three chromosomes simultaneously in each cycle of hybridization, so that 19 pairs of chromosomes of poplar species can be accurately identified.The method has the advantages of good universality in poplar species, good experimental repeatability and high resolution.The methoddisclosed by the invention provides a novel method for accurately identifying each chromosome of the poplar species, and lays a solid working foundation for molecular cytogenetics research of poplar.

The invention discloses a colloidal gold immunodetection kit for detecting a transgenic protein Cry1Ab/Ac. The colloidal gold immunodetection kit comprises a pretreatment PCR tube and a test paper. The test paper is composed of a sample pad, a label pad, a nitrocellulose membrane and an absorbent pad, and the sample pad, the label pad, the nitrocellulose membrane and the absorbent pad are orderly lap-connected to and bonded to a base plate. The label pad is coated with a colloidal gold-labeled anti-digoxin antibody. The nitrocellulose membrane comprises a detection zone coated with an anti-FITC antibody and a control zone coated with a secondary antibody. The pretreatment PCR tube comprises a digoxin-labeled sequence, a FITC-labeled sequence, a Taq enzyme, dNTP and buffer. The digoxin-labeled sequence is GCTCCTACAAATGCCATCATTGC and the FITC-labeled sequence is GATAGTGGGATTGTGCGTCATCCC. The colloidal gold immunodetection card can realize fast and on-site sensitive detection of the PCR amplification product, is easy to operate, realizes visual inspection of the PCR amplification result and can finish detection in 8-10min.

The invention relates to an in-situ hybridization detection probe of shrimp and crab spiroplasma pathogens, and a kit thereof. The sequences of the probe are represented by SEQIDNO.1 and SEQIDNO.2 respectively. The above two oligonucleotide probes are labeled with digoxin, the labeled probes are hybridized with spiroplasma 16SrDNA in shrimp and crab tissue slices, signal enlargement is carried out through an antigen-antibody reaction, and then enzyme reaction color development is carried out; the pathogen detection and pathological change can be visually combined; the infection rate and the infection intensity are analyzed on sample slices while spiroplasma is efficiently and accurately detected; the hybridization of the probes and the 16SrDNA is specific, and the signal is amplified step by step, so the probes are more sensitive and accurate than routine dyeing observation; and the slices obtained after the detection result hybridization color development can be preserved for a long term.

The invention discloses an Eriocheir sinensis Microsporidia in-situ hybridization detection probe and kit. The sequence of the probe is disclosed as SEQ ID NO.1. After the probe is labeled by digoxin and combined with Microsporidia 18S subunit ribosome DNA (18S SSU rDNA) by hybridization, the Microsporidia infection can be judged under a microscope after alkaline phosphatase detection system color development. The invention also discloses a kit containing the probe, which has favorable specific, is simple to operate and can intuitively combine the pathogen detection and pathological changes. On the premise of efficiently and accurately detecting the Spiroplasma, the kit can analyze the infection rate and infection intensity of the sample section. The hybridization between the probe and 18S SSU rDNA is specific, the signal is progressively amplified, and thus, the kit disclosed by the invention is more sensitive and accurate than the conventional dyeing observation detection. The detection result proves that the section subjected to hybridization color development can be stored for a long time.

The invention belongs to the technical field of medical appliances, and discloses a kit which comprises primary antibody digoxin antibody, secondary antibody rat anti-goat IgG, 3H labeled divaricoside, polyethyleneglycol 6000, phosphate buffer solution (PBS) with the pH value of 7.4, 3H scintillation solution, and tris(hydroxymethyl)metyl aminomethan buffer solution (Tris buffer solution) with the pH value of 7.4, and/or divaricoside. The kit provided by the invention is simple and convenient to operate, has the advantages of high sensitivity, high specificity and the like, and can perform stable and reliable early diagnosis on gestational period eclamptism, thereby providing favorable support for subsequent treatment.

The invention discloses a novel digoxin preparation and a method of preparing the novel digoxin preparation. Digoxin, a bonding agent, a filling agent and the like are used as raw materials, and through methods such as dry granulation tablet compression, wet granulation tablet compression and top jet fluidized bed granulation tablet compression, the novel digoxin preparation with good compressibility is prepared. According to the novel digoxin preparation, for patients who need to take a precise amount of medicine, a small dose of medicine can be applied to the patients multiple times, particularly for people with large individual metabolism difference, counting can be conducted during medicine taking, for people who have difficulty in taking common preparations, the adaptability of medicine taking can be improved, the adopted method is simple, the raw materials are easily obtained, and industrial production is facilitated.